OKYO Pharma Limited’s Quiet Period Set To End on June 27th (NASDAQ:OKYO)

OKYO Pharma’s (NASDAQ:OKYOGet Rating) quiet period is set to end on Monday, June 27th. OKYO Pharma had issued 625,000 shares in its initial public offering on May 17th. The total size of the offering was $2,500,000 based on an initial share price of $4.00. During OKYO Pharma’s quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

NASDAQ:OKYO opened at $2.17 on Friday. OKYO Pharma has a 12-month low of $1.88 and a 12-month high of $6.11.

OKYO Pharma Company Profile (Get Rating)

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.

Read More

Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.